JBCHEPHARMJB Chemicals & Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on JBCHEPHARM — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • ROE: 18.7%
- • ROCE: 21.6%
- • Debt/Equity: 0.00
- • RSI: 61
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • ROE: 18.7%
- • ROCE: 21.6%
- • Debt/Equity: 0.00
- • RSI: 61
Bear case
- • Revenue growth: -4.8% YoY
- • Profit growth: -31.0% YoY
- • MACD: bearish
- • Volume: 0.0x 20-day average
Key risks
- • Revenue growth: -4.8% YoY
- • Profit growth: -31.0% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹40.08). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.